Canaccord analyst William Plovanic lowered the firm’s price target on Neuronetics to $3 from $6 and keeps a Buy rating on the shares. The firm said Q2 missed estimates driven by low treatment session revenue as customers delayed refilling inventory due to continued prior authorization and reimbursement headwinds from Change Healthcare’s cybersecurity breach impacting Neuronetics’ customer base.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STIM:
- Neuronetics Announces Strategic Acquisition of Greenbrook TMS
- Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge
- Neuronetics (STIM) Q2 Earnings Cheat Sheet
- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Neuronetics partners with non-profit This Is My Brave